Top

Published in:

01-04-2022 | Breast Cancer | Original Article

A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel

Authors: Keivan Majidzadeh-A, Shiva Zarinfam, Nasrin Abdoli, Fatemeh Yadegari, Rezvan Esmaeili, Leila Farahmand, Azin Teimourzadeh, Mahdieh Taghizadeh, Mansoor Salehi, Mohamad Zamani

Published in: Familial Cancer | Issue 2/2022

Abstract

BRCA1 and BRCA2 are two prominent genes that account for about 20–40% of inherited breast cancer. Mutations in these genes are often associated with clustering of especially early-onset cancers in the family. The spectrum of BRCA variants showed a significant difference between geographic regions and ethnicities. The frequency and spectrum of BRCA mutations in Iran, a country in southwest Asia, have not yet been thoroughly studied. Here, for the first time, all published and not published BRCA pathogenic variants are presented. Among 1040 high risk families (1258 cases) which were detected, 116 families were found to carry pathogenic variants in either BRCA1 or BRCA2. Altogether 89 distinct types of pathogenic variants have been detected in Iran, including 41 in BRCA1 and 48 in BRCA2. 16 out of 89 mutations had not been previously reported in Iran and are presented for the first time in this article, among which 4 mutations are novel worldwide. 20% of families had one of the seven most commonly observed mutations, including c.81-1G > C, c.66_67delAG, c.4609C>T, c.1568delT, c.1961delA, in BRCA1 and: c.3751_3752insA, c.8585dupT in BRCA2. Combining the data from published articles and our study which has not been published before, a comprehensive table is created as a reference for entire BRCA pathogenic variants and their frequencies in Iran.

Available only for authorised users

Boyle P, Levin B (2008) World cancer report 2008. IARC Press, International Agency for Research on Cancer, Lyon

U.S. Cancer Statistics Working Group (2017) United states cancer statistics: 1999–2014 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute

Mousavi SM, Montazeri A, Mohagheghi MA et al (2007) Breast cancer in Iran: an epidemiological review. Breast J 13(4):383–391CrossRef

Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A (2000) Breast cancer in Iran: a review of 903 case records. Public Health 114(2):143–145PubMed

Loghmani H, Noruzinia M, Abdul Tehrani H, Taghizadeh M, Mohammad Hamid K (2014) Association of estrogen receptors’ promoter methylation and clinicopathological characteristics in Iranian patients with breast cancer. Mol Biochem Diagn J 1(1):21–33

El Saghir NS, Khalil MK, Eid T et al (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int Surg J 5(4):225–233. https://doi.org/10.1016/j.ijsu.2006.06.015CrossRef

Ford D, Easton D, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62(3):676–689. https://doi.org/10.1086/301749CrossRefPubMedPubMedCentral

Janavičius R (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1(3):397–412. https://doi.org/10.1007/s13167-010-0037-yCrossRefPubMedPubMedCentral

Zhang J, Fackenthal JD, Zheng Y, Huo D, Hou N, Niu Q, Zvosec C, Ogundiran TO, Hennis AJ, Leske MC (2012) Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat 134(2):889–894. https://doi.org/10.1007/s10549-012-2136-zCrossRefPubMed

10.

Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D (2015) Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer 121(3):372–378. https://doi.org/10.1002/cncr.29058CrossRefPubMed

11.

Kang E, Seong M-W, Park SK, Lee JW, Lee J, Kim LS, Lee JE, Kim SY, Jeong J, Han SA (2015) The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat 151(1):157–168. https://doi.org/10.1007/s10549-015-3377-4CrossRefPubMed

12.

Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408. https://doi.org/10.1056/NEJM199705153362001CrossRefPubMed

13.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64(4):963–970. https://doi.org/10.1086/302320CrossRefPubMedPubMedCentral

14.

Warner E, Foulkes W, Goodwin P et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247. https://doi.org/10.1093/jnci/91.14.1241CrossRefPubMed

15.

Yassaee VR, Zeinali S, Harirchi I et al (2002) Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res 4(4):R6. https://doi.org/10.1186/bcr443CrossRefPubMedPubMedCentral

16.

Yassaee VR, Ravesh Z, Soltani Z et al (2016) Mutation spectra of BRCA genes in Iranian women with early onset breast cancer - 15 years experience. Asian Pac J Cancer Prev 17(S3):149–153. https://doi.org/10.7314/apjcp.2016.17.s3.149CrossRefPubMed

17.

Pietschmann A, Mehdipour P, Mehdipour P et al (2005) Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families. J Cancer Res Clin Oncol 131(8):552–558. https://doi.org/10.1007/s00432-005-0678-8CrossRefPubMed

18.

Keshavarzi F, Noughani AE, Ayoubian M, Zeinali S (2011) Sequence variants of BRCA1 and BRCA2 genes in four Iranian families with breast and ovarian cancer. Iran J Public Health 40(2):57–66PubMedPubMedCentral

19.

Keshavarzi F, Javadi GR, Zeinali S (2012) BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer 11(1):57–67. https://doi.org/10.1007/s10689-011-9477-3CrossRefPubMed

20.

Saleh-Gohari N, Mohammadi-Anaie M, Kalantari-Khandani B (2012) BRCA1 gene mutations in breast cancer patients from Kerman Province, Iran. Iran J Cancer Prev 5(4):210–215PubMedPubMedCentral

21.

Zorrieh Zahra A, Kadkhoda S, Behjati F et al (2016) Mutation screening of BRCA genes in 10 Iranian males with breast cancer. Int J Mol Cell Med 5(2):114–122PubMedPubMedCentral

22.

Tabarestani S, Motallebi M, Akbari ME, Moghani MM, Shojaee L (2017) Analysis of BRCA1/2 mutations and performance of manchester scoring system in high risk Iranian breast cancer patients: a pilot study. Int J Cancer Manag 10(12):e60392. https://doi.org/10.5812/ijcm.60392CrossRef

23.

Mehrgou A, Akouchekian M, Hemati S (2018) Investigating of variations in BRCA1 gene in Iranian families with breast cancer. Med J Islam Repub Iran 32:87. https://doi.org/10.14196/mjiri.32.87CrossRefPubMedPubMedCentral

24.

Laitman Y, Friebel TM, Yannoukakos D et al (2019) The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in middle eastern, north african, and south european countries. Hum Mutat 40(11):e1–e23. https://doi.org/10.1002/humu.23842CrossRefPubMed

25.

Ebrahimi E, Sellars E, Shirkoohi R et al (2019) The NCCN criterion “young age at onset” alone is not an indicator of hereditary breast cancer in Iranian population. Cancer Prev Res 12(11):763–770. https://doi.org/10.1158/1940-6207.CAPR-19-0056CrossRef

26.

Moslehi R, Karimi-Nejad MH, Ghafari V, Narod S (2003) Analysis of BRCA1 and BRCA2 mutations in an Iranian family with hereditary breast and ovarian cancer syndrome. Am J Med Genet A 117(3):304–305. https://doi.org/10.1002/ajmg.a.10031CrossRef

27.

Ataei-Kachouei M, Nadaf J, Akbari MT et al (2015) Double heterozygosity of BRCA2 and STK11 in familial breast cancer detected by exome sequencing. Iran J Public Health 44(10):1348–1352PubMedPubMedCentral

28.

Bruchim Bar-Sade R, Kruglikova A, Modan B et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 7(5):801–805. https://doi.org/10.1093/hmg/7.5.801CrossRef

29.

Ghaderi A, Talei A, Farjadian S, Mosalaei A, Doroudchi M, Kimura H (2001) Germline BRCA1 mutations in Iranian women with breast cancer. Cancer Lett 165(1):87–94. https://doi.org/10.1016/S0304-3835(01)00394-9CrossRefPubMed

30.

Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A (2013) Identification of germline BRCA1 mutations among breast cancer families in northeastern Iran. Asian Pac J Cancer Prev 14(7):4339–4345. https://doi.org/10.7314/APJCP.2013.14.7.4339CrossRefPubMed

31.

Mehdipour P, Hosseini-Asl S, Savabi-E A, Habibi L, Alvandi E, Atri M (2006) Low frequency of 185delAG founder mutation of BRCA1 gene in Iranian breast cancer patients. J Cancer Mol 2(3):123–127

32.

Rassi H, Gorovenko N, Houshmand M et al (2008) Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histological specimens. Cytol Genet 42(2):120–126. https://doi.org/10.1007/s11956-008-2010-4CrossRef

33.

Fattahi MJ, Mojtahedi Z, Karimaghaee N, Talei A-R, Banani SJ (2009) Analysis of BRCA1 and BRCA2 mutations in southern Iranian breast cancer patients. Arch Iran Med 12(6):584–587PubMed

34.

Bogdanova N, Antonenkova N, Rogov Y, Karstens J, Hillemanns P, Dörk T (2010) High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet 78(4):364–372. https://doi.org/10.1111/j.1399-0004.2010.01473.xCrossRefPubMed

35.

Thorlacius S, Struewing JP, Hartage P et al (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352(9137):1337–1339. https://doi.org/10.1016/S0140-6736(98)03300-5CrossRefPubMed

36.

Hartwig M, Janiszewska H, Bąk A et al (2013) Prevalence of the BRCA1 c. 68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country. Contemp Oncol 17(1):34–37. https://doi.org/10.5114/wo.2013.33767CrossRef

37.

Osorio A, Robledo M, Albertos J et al (1998) Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families. Cancer Lett 123(2):153–158. https://doi.org/10.1016/S0304-3835(97)00416-3CrossRefPubMed

38.

Sokolenko AP, Mitiushkina NV, Buslov KG et al (2006) High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 42(10):1380–1384. https://doi.org/10.1016/j.ejca.2006.01.050CrossRefPubMed

39.

Kroiss R, Winkler V, Bikas D et al (2005) Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. Hum Mutat 26(6):583–539. https://doi.org/10.1002/humu.20261CrossRefPubMed

40.

Wappenschmidt B, Becker AA, Hauke J et al (2012) Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. PLoS ONE 7(12):e50800. https://doi.org/10.1371/journal.pone.0050800CrossRefPubMedPubMedCentral

41.

de Juan JI, Casado ZG, Suela SP et al (2013) Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Fam Cancer 12(4):767–777. https://doi.org/10.1007/s10689-013-9622-2CrossRef

42.

Kim H, Cho DY, Choi DH et al (2012) Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 134(3):1315–1326. https://doi.org/10.1007/s10549-012-2159-5CrossRefPubMed

43.

Ou J, Wu T, Sijmons R, Ni D, Xu W, Upur H (2013) Prevalence of BRCA1 and BRCA2 germline mutations in breast cancer women of multiple ethnic region in northwest China. J Breast Cancer 16(1):50–54. https://doi.org/10.4048/jbc.2013.16.1.50CrossRefPubMedPubMedCentral

Title: A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel
Authors: Keivan Majidzadeh-A
Shiva Zarinfam
Nasrin Abdoli
Fatemeh Yadegari
Rezvan Esmaeili
Leila Farahmand
Azin Teimourzadeh
Mahdieh Taghizadeh
Mansoor Salehi
Mohamad Zamani
Publication date: 01-04-2022
Publisher: Springer Netherlands
Keywords: Breast Cancer
Breast Cancer
Published in: Familial Cancer / Issue 2/2022
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-021-00242-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Questioning the validity of clinically available breast cancer polygenic risk scores: comparison of two labs reveals discrepancies

“I wish that there was more info”: characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants

Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators

Von Hippel-Lindau disease and rapidly progressing pheochromocytomas in siblings

CDH1 pathogenic variants and cancer risk in an unselected patient population

The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management

Keynote webinar | Spotlight on antibody–drug conjugates in cancer